January 2024 in “International Journal of Molecular Sciences” This study found that subcutaneous injection of a CXCL12 neutralizing antibody significantly promoted hair growth in androgenic alopecia and inhibited hair loss in alopecia areata in mouse models, suggesting its potential as a promising treatment for hair loss.
This study discusses a potential new treatment called AMPLEX PLUS that may significantly slow hair loss and stimulate new hair growth by influencing the transition of hair follicles from the telogen phase to the active anagen phase.
37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.
This article discusses the nature and causes of hair loss, including hereditary factors, but reports no new clinical findings.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
August 2014 in “Journal of drug discovery and therapeutics” This review discusses the diagnosis, pathophysiology, growth cycle, and medical treatment of androgenetic alopecia and offers no new clinical results.
2 citations
,
October 2010 in “Journal of dermatological treatment” In this study, researchers observed that in nude mice, exogenous stimulations lengthened the hair-existing phase and shortened the no-hair phase, with minoxidil influencing male and female mice differently.
370 citations
,
September 1999 in “The New England Journal of Medicine” This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.
